Literature DB >> 9346389

Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis.

K Matsumoto1, H Ohi, K Kanmatsuse.   

Abstract

It has been proposed that a vascular permeability factor (VPF) is involved in the pathogenesis of lipoid nephrosis (LN). There is now increasing evidence that interleukin 10 (IL-10) and interleukin 13 (IL-13) have regulatory effects on cytokine production by activated macrophages. These results prompted us to study the effects of recombinant human IL-10 and IL-13 on VPF secretion in LN. In the present study, we demonstrate that the regulatory cytokines IL-10 and IL-13 are potent inhibitors of the VPF activity of activated peripheral blood mononuclear cells. Each cytokine was found to suppress VPF secretion in a dose-dependent fashion. More importantly, the combination of the cytokines was found to give a potent synergistic suppression of VPF by concanavalin A activated peripheral blood mononuclear cells from patients with LN. When both anti-IL-10 and anti-IL-13 antibodies were added together to the peripheral blood mononuclear cells, a further increase of concanavalin A enhanced secretion of VPF occurred. These data establish IL-10 and IL-13 as potent inhibitors of VPF activity and suggest their utility in controlling deleterious VPF-mediated responses such as occur in LN patients with nephrotic syndrome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9346389     DOI: 10.1159/000190275

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury.

Authors:  J Corne; G Chupp; C G Lee; R J Homer; Z Zhu; Q Chen; B Ma; Y Du; F Roux; J McArdle; A B Waxman; J A Elias
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

2.  Increased IL-12 release by monocytes in nephrotic patients.

Authors:  K Matsumoto; K Kanmatsuse
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

3.  Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation.

Authors:  Anupama E Gururaj; Madesh Belakavadi; Bharathi P Salimath
Journal:  Mol Cell Biochem       Date:  2003-01       Impact factor: 3.396

4.  Kaposi's sarcoma-associated herpesvirus induces sustained levels of vascular endothelial growth factors A and C early during in vitro infection of human microvascular dermal endothelial cells: biological implications.

Authors:  Ramu Sivakumar; Neelam Sharma-Walia; Hari Raghu; Mohanan Valiya Veettil; Sathish Sadagopan; Virginie Bottero; Laszlo Varga; Rita Levine; Bala Chandran
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

5.  Vascular Aging: Implications for Cardiovascular Disease and Therapy.

Authors:  Yohannes T Ghebre; Eduard Yakubov; Wing Tak Wong; Prasanna Krishnamurthy; Nazish Sayed; Andrew G Sikora; Mark D Bonnen
Journal:  Transl Med (Sunnyvale)       Date:  2016-08-30

6.  Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors.

Authors:  Dawid G Nowak; Jeanette Woolard; Elianna Mohamed Amin; Olga Konopatskaya; Moin A Saleem; Amanda J Churchill; Michael R Ladomery; Steven J Harper; David O Bates
Journal:  J Cell Sci       Date:  2008-10-15       Impact factor: 5.285

7.  Interleukin-13 inhibits cytokines synthesis by blocking nuclear factor-κB and c-Jun N-terminal kinase in human mesangial cells.

Authors:  Chunhua Zhu; Aihua Zhang; Songming Huang; Guixia Ding; Xiaoqin Pan; Ronghua Chen
Journal:  J Biomed Res       Date:  2010-07

8.  VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma.

Authors:  Sutapa Sinha; Ying Cao; Shamit Dutta; Enfeng Wang; Debabrata Mukhopadhyay
Journal:  J Cell Mol Med       Date:  2008-11-07       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.